Step Therapy - Bosulif (bosutinib)
UnitedHealthcare pharmacy step therapy program requiring trial or physician consideration of imatinib and trial of or contraindication to nilotinib (Tasigna) before covering Bosulif (bosutinib) for Philadelphia chromosome-positive chronic myelogenous/myeloid leukemia (CML). Applies to pharmacy coverage; members <19 auto-process without review.
Annual reviews noted with no change to clinical coverage criteria; background and references updated periodically.
Coverage Criteria for Bosulif (bosutinib)
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.